Hapag-Lloyd Revises $4.2 Billion Bid for Israel’s ZIM After Security Concerns
New terms keep Israeli control and limit foreign ownership.
Already have an account? Sign in.
New terms keep Israeli control and limit foreign ownership.
HARMONi-2: Summit’s Ivonescimab extended median survival by 8.2 months vs Keytruda. 42% lower death risk in PD-L1-high patients.
Citi calls Olema’s drop after AstraZeneca’s SERENA-4 miss excessive, keeps Buy and $59 target, and sees $20 value from later-line use.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.